178 related articles for article (PubMed ID: 29174504)
1. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
[TBL] [Abstract][Full Text] [Related]
2. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.
Reis LO; Ferreira U; Billis A; Cagnon VH; Fávaro WJ
J Urol; 2012 Feb; 187(2):438-45. PubMed ID: 22177150
[TBL] [Abstract][Full Text] [Related]
5. Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guérin on precancerous lesions of bladder in a rat model.
Teke K; Yilmaz H; Uslubas AK; Akpinar G; Kasap M; Mutlu O; Yildiz DK; Guzel N; Dillioglugil O
Int Urol Nephrol; 2018 Aug; 50(8):1417-1425. PubMed ID: 29931492
[TBL] [Abstract][Full Text] [Related]
6. Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-guérin association.
Kiehl IGA; Riccetto E; Salustiano ACC; Ossick MV; Ferrari KL; Assalin HB; Ikari O; Reis LO
World J Urol; 2021 Apr; 39(4):1187-1194. PubMed ID: 32488358
[TBL] [Abstract][Full Text] [Related]
7. Castration immunoregulates toll-like receptor-4 in male bladder cancer.
Reis LO; Salustiano ACC; Capibaribe DM; Kiehl IGA; Denardi F
Int Urol Nephrol; 2022 Nov; 54(11):2845-2853. PubMed ID: 35939229
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
9. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
[TBL] [Abstract][Full Text] [Related]
10. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
11. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
World J Urol; 2018 Nov; 36(11):1719-1725. PubMed ID: 29767328
[TBL] [Abstract][Full Text] [Related]
13. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2011 Jan; 185(1):67-71. PubMed ID: 21074202
[TBL] [Abstract][Full Text] [Related]
17. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
[TBL] [Abstract][Full Text] [Related]
18. [Effect of intravesical bacillus Calmette-Guérin on N-butyl-N-(4-hydroxybutyl)-nitrosamine induced urinary bladder carcinogenesis in rats].
Yanagisawa T; Suzuki T; Kudoh T; Oh SC
Nihon Hinyokika Gakkai Zasshi; 1994 Jun; 85(6):945-52. PubMed ID: 8065076
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
20. Carcinogenesis and Bacillus Calmette-Guérin (BCG) Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer under Tryptophan and Thymine Supplementation.
Ossick MV; Assalin HB; Kiehl IGA; Salustiano ACC; Rocha GZ; Ferrari KL; Linarelli MCB; Degasperi G; Reis LO
Nutr Cancer; 2021; 73(11-12):2687-2694. PubMed ID: 33287590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
